Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Osteochondrodysplasia Clear all
Terminated Phase 3 Interventional Results available

Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI

NCT02352753
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Denosumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
2 Years to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2022 · Synced Jul 23, 2026, 11:09 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of LY3200882 in Participants With Solid Tumors

NCT02937272
View directory record Official record
Conditions
Solid Tumor
Interventions
LY3200882, LY3300054, Gemcitabine, nab-Paclitaxel, Cisplatin, Intensity Modulated Radiotherapy
Drug · Radiation
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

NCT04035811
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impact of B. Adolescentis iVS-1 Probiotic on Gastrointestinal Outcomes

NCT07408518
View directory record Official record
Conditions
Digestive Disease, Gut Health
Interventions
Probiotic, Placebo
Dietary Supplement · Other
Lead sponsor
Synbiotic Health
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

Genetic Analysis of the Chiari I Malformation

NCT00004738
View directory record Official record
Conditions
Syringomyelia, Type I Arnold Chiari Malformation
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Year and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03424018
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
6 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

Screening an Orthopedic Population for Mildly-affected Individuals With Morquio Syndrome A and Maroteaux-Lamy Syndrome

NCT01961518
View directory record Official record
Conditions
Morquio Syndrome A, Maroteaux Lamy Syndrome, MPS IVA, MPS VI
Interventions
Not listed
Lead sponsor
Greenwood Genetic Center
Other
Eligibility
Up to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Jul 23, 2026, 11:09 AM EDT
Active, not recruiting Phase 2 Interventional

Denosumab Treatment for Fibrous Dysplasia

NCT03571191
View directory record Official record
Conditions
Bone Diseases, Pain
Interventions
Denosumab
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jul 23, 2026, 11:09 AM EDT
Completed Not applicable Interventional Results available

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779
View directory record Official record
Conditions
Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions
Pre-visit prep, usual care + exome seq
Behavioral · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 23, 2026, 11:09 AM EDT
Not listed Not applicable Interventional

Evaluation of Skeletal Maturity for Slipped Capital Femoral Epiphysis

NCT01220882
View directory record Official record
Conditions
Slipped Capital Femoral Epiphysis
Interventions
Radiographic skeletal age assessment
Radiation
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
8 Years to 16 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Jul 23, 2026, 11:09 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Characterization of Diabetes Mellitus in Fibrous Dysplasia/McCune-Albright Syndrome

NCT03520153
View directory record Official record
Conditions
McCune-Albright Syndrome, Fibrous Dysplasia, Intraductal Papillary Mucinous Neoplasm, Diabetes Mellitus
Interventions
Hyperinsulinemic Euglycemic Clamp and 2H20, Hyperglycemic Clamp, Oral Glucose Tolerance Test
Procedure · Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS)

NCT02294877
View directory record Official record
Conditions
Mucopolysaccharidosis IV Type A, Morquio A Syndrome, MPS IVA
Interventions
Vimizim® (elosulfase alfa)
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
Not listed
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Jul 23, 2026, 11:09 AM EDT
Recruiting No phase listed Observational

Prospective Clinical Assessment Study in Children With Hypochondroplasia

NCT06410976
View directory record Official record
Conditions
Hypochondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 16 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Angiotensin II Antagonism of TGF-Beta 1

NCT00320970
View directory record Official record
Conditions
Diabetic Nephropathy, Hypertension
Interventions
Candesartan
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Aug 1, 2007 · Synced Jul 23, 2026, 11:09 AM EDT
Recruiting No phase listed Observational

BBD Longitudinal Study of Osteogenesis Imperfecta

NCT02432625
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
11
States / cities
Phoenix, Arizona • Los Angeles, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 11:09 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

NCT04066491
View directory record Official record
Conditions
Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer
Interventions
M7824, Placebo, Gemcitabine, Cisplatin
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chandler, Arizona • Gilbert, Arizona • Phoenix, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

Issues Surrounding Prenatal Genetic Testing for Achondroplasia

NCT00001536
View directory record Official record
Conditions
Achondroplasia, Dwarfism
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jul 23, 2026, 11:09 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Loss of Y Chromosome in Aortic Stenosis

NCT06595407
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Blood analysis for loss-of-Y chromosome
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
40 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 23, 2026, 11:09 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

NCT04501094
View directory record Official record
Conditions
Urothelial Cancer
Interventions
Bintrafusp alfa (M7824)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Jul 23, 2026, 11:09 AM EDT
Completed Phase 4 Interventional Results available

Study of Teriparatide (FORTEO) to Treat Adults With Osteogenesis Imperfecta

NCT00131469
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Teriparatide (FORTEO), Placebos
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
3
States / cities
Baltimore, Maryland • Portland, Oregon • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 23, 2026, 11:09 AM EDT
Terminated Phase 3 Interventional Results available

Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta

NCT03638128
View directory record Official record
Conditions
Osteogenesis Imperfecta (OI)
Interventions
Denosumab, Alternative osteoporosis medications
Drug
Lead sponsor
Amgen
Industry
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Los Angeles, California • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Dec 19, 2022 · Synced Jul 23, 2026, 11:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Urinary Biomarkers of OI Pathobiology

NCT02531087
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Omaha, Nebraska • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Jul 23, 2026, 11:09 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia

NCT06164951
View directory record Official record
Conditions
Achondroplasia
Interventions
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day
Drug
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
3 Years to 17 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Jul 23, 2026, 11:09 AM EDT
Completed No phase listed Observational

Evaluation and Intervention for the Effects of Osteogenesis Imperfecta

NCT00001594
View directory record Official record
Conditions
Osteogenesis Imperfecta
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Up to 10 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 11:09 AM EDT